Pfizer Sildenafil 50mg for Pulmonary Hypertension

The overall frequency of discontinuation in REVATIO-treated patients on 20 mg three

In case of emergency/overdose

Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II–III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%). Limitation of Use: Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see Clinical Studies (14)]. The recommended dose of REVATIO is 5 mg or 20 mg three times a day. Administer REVATIO doses 4–6 hours apart. In the clinical trial no greater efficacy was achieved with the use of higher doses.

When to call your doctor

Treatment with doses higher than 20 mg three times a day is not recommended. REVATIO injection is for the continued treatment of patients with PAH who are currently prescribed oral REVATIO and who are temporarily unable to take oral medication. The recommended dose is 2.5 mg or 10 mg administered as an intravenous bolus injection three times a day. The dose of REVATIO injection does not need to be adjusted for body weight. A 10 mg dose of REVATIO injection is predicted to provide pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose. times a day was 3% and was the same for the placebo group.

• Pfizer sildenafil 50mg is often taken on an as-needed basis.
• It is important to avoid taking it with certain medications like thiazide diuretics.
• Sildenafil is not intended for daily continuous use unless prescribed.
• Side effects can include vision changes like blue tinge or blurred vision.
• Long-term safety of sildenafil is generally well-established when used properly.
• The drug works by relaxing blood vessels in the lungs as well.
• It is vital to disclose all health conditions before starting therapy.
• Regular medical follow-up can help monitor medication effects.

In Study 1, the adverse reactions that were reported by at least 3% of REVATIO-treated patients (20 mg three

times a day) and were more frequent in REVATIO-treated patients than in placebo-treated patients are shown in Table 1.

Drug Food Interaction

In some of the cases, medical conditions and other factors were reported that may have played a role. It is not possible to determine whether these reported events are related directly to the use of REVATIO, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors. Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE-5 inhibitors, including REVATIO. The safety and efficacy of combinations of REVATIO with VIAGRA or other PDE-5 inhibitors have not been studied. Inform patients taking REVATIO not to take VIAGRA or other PDE-5 inhibitors. Adverse reactions were generally transient and mild to moderate in nature.

What is Viagra?

REVATIO has vasodilatory properties, resulting in mild and transient decreases in blood pressure. Before prescribing REVATIO, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension [BP less than 90/50], fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction). Monitor blood pressure when co-administering blood pressure lowering drugs with REVATIO. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of REVATIO to patients with veno-occlusive disease, administration of REVATIO to such patients is not recommended.

Is Viagra dosage based on age or weight?

Should signs of pulmonary edema occur when REVATIO is administered, consider the possibility of associated PVOD. The incidence of epistaxis was 13% in patients taking REVATIO with PAH secondary to CTD. This effect was not seen in idiopathic PAH (REVATIO 3%, placebo 2%) patients. The incidence of epistaxis was also higher in REVATIO-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist). The safety of REVATIO is unknown in patients with bleeding disorders or active peptic ulceration. At doses higher than the recommended 20 mg three times a day, there was

• Pfizer sildenafil 50mg is available in various pack sizes depending on prescription.
• The medication is sometimes used in clinical trials for other indications.
• Proper storage and handling extend the shelf life of sildenafil.
• Report any allergic reactions to your healthcare provider immediately.
• Sildenafil's patent expiry has increased availability of generic options.
• Patients should avoid using it if they have certain eye conditions.
• Regular blood pressure monitoring may be recommended during treatment.
• Follow-up appointments are important for monitoring efficacy and safety.

a greater incidence of some adverse reactions including flushing, diarrhea, myalgia and visual disturbances. Visual disturbances were identified as mild and transient, and were predominately

• Pfizer sildenafil 50mg is often prescribed after assessing cardiovascular health.
• It is important to follow dosing instructions to prevent side effects.
• Sildenafil is sometimes used off-label for other medical conditions.
• Men should seek emergency help for prolonged erections lasting over 4 hours.
• Use of sildenafil in combination with other ED treatments should be guided by a doctor.
• The medication can cause low blood pressure in some individuals.
• Adherence to medical advice ensures optimal treatment results.
• Extended use without medical supervision is not recommended.

color-tinge to vision, but also increased sensitivity to light or blurred vision.

See also:

Note: Reconstitute the contents of the bottle with a total volume of 90 mL (60 mL followed by 30 mL). Tap the bottle to release the powder. Accurately measure out 60 mL of water and pour the water into the bottle. Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. Accurately measure out another 30 mL of water and add this to the bottle.

Revatio Injection

You should always add a total of 90 mL of water irrespective of the dose prescribed. Press the bottle adaptor into the neck of the bottle (as shown on Figure 5, below). The adaptor is provided so that you can fill the oral syringe with medicine from the bottle. Replace the cap on the bottle.Figure 5 Write the expiration date of the reconstituted oral suspension on the bottle label (the expiration date of the reconstituted oral suspension is 60 days from the date of reconstitution). White, film-coated, round tablets engraved with "RVT20" containing sildenafil citrate equivalent to 20 mg of sildenafil. The incidence of retinal hemorrhage with REVATIO 20 mg three times a day was

Images for Pfizer VGR 50

When used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, sildenafil pfizer 100g including sildenafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio ("crowded disc"), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. Based on published literature, the annual incidence of NAION is 2.5–11.8 cases per 100,000 males aged ≥ 50 per year in the general population. An observational case-crossover study evaluated the risk of NAION when PDE-5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE-5 inhibitor use in a prior time period. Neither the rare postmarketing reports, nor the association of PDE-5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE-5 inhibitor use and NAION [see Adverse Reactions (6.2].

Sildenafil Tablets for ED

Advise patients to seek immediate medical attention in the event of a sudden loss of vision in one or both eyes while taking PDE-5 inhibitors, including REVATIO. Physicians should also discuss the increased risk of NAION with patients who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such as PDE-5 inhibitors. There are no controlled sildenafil 200 mg clinical data on the safety or efficacy of REVATIO in patients with retinitis pigmentosa, a minority whom have genetic disorders of retinal phosphodiesterases. Prescribe REVATIO with caution in these patients. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in temporal association with the use of PDE-5 inhibitors, including REVATIO. 1.4% versus 0% placebo and for all REVATIO doses studied was 1.9% versus 0% placebo.

More about sildenafil

If priapism (painful erection greater than 6 hours in duration) is not treated immediately, penile tissue damage and permanent loss of potency could result. In a small, prematurely terminated study of patients with pulmonary hypertension (PH) secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received REVATIO than by those randomized to placebo. The effectiveness and safety of REVATIO in the treatment of PAH secondary to sickle cell anemia has not been established. The following serious adverse events are discussed elsewhere in the labeling: Mortality with pediatric use [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)] Hypotension [see Warnings and Precautions (5.2)] Vision loss [see Warnings and Precautions (5.5)] Hearing loss [see Warnings and Precautions (5.6)] Priapism [see Warnings and Precautions (5.8)] Vaso-occlusive crisis [see Warnings and Precautions (5.9)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Safety data of REVATIO in adults were obtained from the 12-week, placebo-controlled clinical study (Study 1) and an open-label extension study in 277 REVATIO-treated patients with PAH, WHO Group I [see Clinical Studies (14)]. The incidence of eye hemorrhage at both 20 mg three times a day

and at all doses studied was 1.4% for REVATIO versus 1.4% for placebo.

Warnings & Precautions

White to off-white powders containing 1.57 g of sildenafil citrate (equivalent to 1.12 g of sildenafil) in a bottle intended for reconstitution. Following reconstitution with 90 mL of water, the volume of the oral suspension is 112 mL and the oral suspension contains 10 mg/mL sildenafil. A 2 mL oral syringe (with 0.5 mL and 2 mL dose markings) and a press-in bottle adaptor are also provided. Concomitant use of organic sildenafil 20 mg tablets nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions (5.2)]. PDE-5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.

What should I do if I accidentally use too much sildenafil?

Known hypersensitivity to sildenafil or any component of the tablet, injection, or oral suspension. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil. In a long-term trial in pediatric patients with PAH, an increase in mortality with increasing REVATIO dose was observed. Deaths were first observed after about 1 year and causes of death were typical of patients with PAH. Use of REVATIO, particularly chronic use, is not recommended in children [see Use in Specific Populations (8.4)].